Necitumumab in metastatic squamous cell lung cancer

Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, Suresh S. Ramalingam, Fadlo R. Khuri, Christopher R. Flowers

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.84). However, the costs and value associated with this intervention remains unclear. Value-based pricing links the price of a drug to the benefit that it provides and is a novelmethod to establish prices for new treatments. OBJECTIVE To evaluate the range of drug costs for which adding necitumumab to chemotherapy could be considered cost-effective. DESIGN, SETTING, AND PARTICIPANTS We developed a Markov model using data from multiple sources, including the SQUIRE trial, which compared standard chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs and patient life expectancies associated with each regimen. In the analysis, patients were modeled to receive gemcitabine and cisplatin for 6 cycles or gemcitabine, cisplatin, and necitumumab for 6 cycles followed by maintenance necitumumab. Our model's clinical inputs were the survival estimates and frequency of adverse events (AEs) described in the SQUIRE trial. Log-logistic models were fitted to the survival distributions in the SQUIRE trial. The cost inputs included drug costs, based on the Medicare average sale prices, and costs for drug administration and management of AEs, based on Medicare reimbursement rates (all in 2014 US dollars). MAIN OUTCOMES AND MEASURES We evaluated incremental cost-effectiveness ratios (ICERs) for the use of necitumumab across a range of values for its cost. Model robustness was assessed by probabilistic sensitivity analyses, based on 10 000 Monte Carlo simulations, sampling values from the distributions of all model parameters. RESULTS In the base case analysis, the addition of necitumumab to the treatment regimen produced an incremental survival benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs). The probabilistic sensitivity analyses established that when necitumumab cost less than $563 and less than $1309 per cycle, there was 90% confidence that the ICER for adding necitumumab would be less than $100 000 per QALY and less than $200 000 per QALY, respectively. CONCLUSIONS AND RELEVANCE These findings provide a value-based range for the cost of necitumumab from $563 to $1309 per cycle. This study provides a framework for establishing value-based pricing for new oncology drugs entering the US marketplace.

Original languageEnglish (US)
Pages (from-to)1293-1300
Number of pages8
JournalJAMA Oncology
Volume1
Issue number9
DOIs
StatePublished - Dec 1 2015

Fingerprint

Squamous Cell Neoplasms
Lung Neoplasms
Costs and Cost Analysis
gemcitabine
Drug Costs
Quality-Adjusted Life Years
Survival
Medicare
Drug Therapy
Cisplatin
Cost-Benefit Analysis
necitumumab
Information Storage and Retrieval
Life Expectancy
Pharmaceutical Preparations
Therapeutics
Logistic Models
Maintenance

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Goldstein, D. A., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., Ramalingam, S. S., ... Flowers, C. R. (2015). Necitumumab in metastatic squamous cell lung cancer. JAMA Oncology, 1(9), 1293-1300. https://doi.org/10.1001/jamaoncol.2015.3316
Goldstein, Daniel A. ; Chen, Qiushi ; Ayer, Turgay ; Howard, David H. ; Lipscomb, Joseph ; Ramalingam, Suresh S. ; Khuri, Fadlo R. ; Flowers, Christopher R. / Necitumumab in metastatic squamous cell lung cancer. In: JAMA Oncology. 2015 ; Vol. 1, No. 9. pp. 1293-1300.
@article{81708a45814f46c1b3c843e3ae577139,
title = "Necitumumab in metastatic squamous cell lung cancer",
abstract = "IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.84). However, the costs and value associated with this intervention remains unclear. Value-based pricing links the price of a drug to the benefit that it provides and is a novelmethod to establish prices for new treatments. OBJECTIVE To evaluate the range of drug costs for which adding necitumumab to chemotherapy could be considered cost-effective. DESIGN, SETTING, AND PARTICIPANTS We developed a Markov model using data from multiple sources, including the SQUIRE trial, which compared standard chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs and patient life expectancies associated with each regimen. In the analysis, patients were modeled to receive gemcitabine and cisplatin for 6 cycles or gemcitabine, cisplatin, and necitumumab for 6 cycles followed by maintenance necitumumab. Our model's clinical inputs were the survival estimates and frequency of adverse events (AEs) described in the SQUIRE trial. Log-logistic models were fitted to the survival distributions in the SQUIRE trial. The cost inputs included drug costs, based on the Medicare average sale prices, and costs for drug administration and management of AEs, based on Medicare reimbursement rates (all in 2014 US dollars). MAIN OUTCOMES AND MEASURES We evaluated incremental cost-effectiveness ratios (ICERs) for the use of necitumumab across a range of values for its cost. Model robustness was assessed by probabilistic sensitivity analyses, based on 10 000 Monte Carlo simulations, sampling values from the distributions of all model parameters. RESULTS In the base case analysis, the addition of necitumumab to the treatment regimen produced an incremental survival benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs). The probabilistic sensitivity analyses established that when necitumumab cost less than $563 and less than $1309 per cycle, there was 90{\%} confidence that the ICER for adding necitumumab would be less than $100 000 per QALY and less than $200 000 per QALY, respectively. CONCLUSIONS AND RELEVANCE These findings provide a value-based range for the cost of necitumumab from $563 to $1309 per cycle. This study provides a framework for establishing value-based pricing for new oncology drugs entering the US marketplace.",
author = "Goldstein, {Daniel A.} and Qiushi Chen and Turgay Ayer and Howard, {David H.} and Joseph Lipscomb and Ramalingam, {Suresh S.} and Khuri, {Fadlo R.} and Flowers, {Christopher R.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1001/jamaoncol.2015.3316",
language = "English (US)",
volume = "1",
pages = "1293--1300",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "9",

}

Goldstein, DA, Chen, Q, Ayer, T, Howard, DH, Lipscomb, J, Ramalingam, SS, Khuri, FR & Flowers, CR 2015, 'Necitumumab in metastatic squamous cell lung cancer', JAMA Oncology, vol. 1, no. 9, pp. 1293-1300. https://doi.org/10.1001/jamaoncol.2015.3316

Necitumumab in metastatic squamous cell lung cancer. / Goldstein, Daniel A.; Chen, Qiushi; Ayer, Turgay; Howard, David H.; Lipscomb, Joseph; Ramalingam, Suresh S.; Khuri, Fadlo R.; Flowers, Christopher R.

In: JAMA Oncology, Vol. 1, No. 9, 01.12.2015, p. 1293-1300.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Necitumumab in metastatic squamous cell lung cancer

AU - Goldstein, Daniel A.

AU - Chen, Qiushi

AU - Ayer, Turgay

AU - Howard, David H.

AU - Lipscomb, Joseph

AU - Ramalingam, Suresh S.

AU - Khuri, Fadlo R.

AU - Flowers, Christopher R.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.84). However, the costs and value associated with this intervention remains unclear. Value-based pricing links the price of a drug to the benefit that it provides and is a novelmethod to establish prices for new treatments. OBJECTIVE To evaluate the range of drug costs for which adding necitumumab to chemotherapy could be considered cost-effective. DESIGN, SETTING, AND PARTICIPANTS We developed a Markov model using data from multiple sources, including the SQUIRE trial, which compared standard chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs and patient life expectancies associated with each regimen. In the analysis, patients were modeled to receive gemcitabine and cisplatin for 6 cycles or gemcitabine, cisplatin, and necitumumab for 6 cycles followed by maintenance necitumumab. Our model's clinical inputs were the survival estimates and frequency of adverse events (AEs) described in the SQUIRE trial. Log-logistic models were fitted to the survival distributions in the SQUIRE trial. The cost inputs included drug costs, based on the Medicare average sale prices, and costs for drug administration and management of AEs, based on Medicare reimbursement rates (all in 2014 US dollars). MAIN OUTCOMES AND MEASURES We evaluated incremental cost-effectiveness ratios (ICERs) for the use of necitumumab across a range of values for its cost. Model robustness was assessed by probabilistic sensitivity analyses, based on 10 000 Monte Carlo simulations, sampling values from the distributions of all model parameters. RESULTS In the base case analysis, the addition of necitumumab to the treatment regimen produced an incremental survival benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs). The probabilistic sensitivity analyses established that when necitumumab cost less than $563 and less than $1309 per cycle, there was 90% confidence that the ICER for adding necitumumab would be less than $100 000 per QALY and less than $200 000 per QALY, respectively. CONCLUSIONS AND RELEVANCE These findings provide a value-based range for the cost of necitumumab from $563 to $1309 per cycle. This study provides a framework for establishing value-based pricing for new oncology drugs entering the US marketplace.

AB - IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.84). However, the costs and value associated with this intervention remains unclear. Value-based pricing links the price of a drug to the benefit that it provides and is a novelmethod to establish prices for new treatments. OBJECTIVE To evaluate the range of drug costs for which adding necitumumab to chemotherapy could be considered cost-effective. DESIGN, SETTING, AND PARTICIPANTS We developed a Markov model using data from multiple sources, including the SQUIRE trial, which compared standard chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs and patient life expectancies associated with each regimen. In the analysis, patients were modeled to receive gemcitabine and cisplatin for 6 cycles or gemcitabine, cisplatin, and necitumumab for 6 cycles followed by maintenance necitumumab. Our model's clinical inputs were the survival estimates and frequency of adverse events (AEs) described in the SQUIRE trial. Log-logistic models were fitted to the survival distributions in the SQUIRE trial. The cost inputs included drug costs, based on the Medicare average sale prices, and costs for drug administration and management of AEs, based on Medicare reimbursement rates (all in 2014 US dollars). MAIN OUTCOMES AND MEASURES We evaluated incremental cost-effectiveness ratios (ICERs) for the use of necitumumab across a range of values for its cost. Model robustness was assessed by probabilistic sensitivity analyses, based on 10 000 Monte Carlo simulations, sampling values from the distributions of all model parameters. RESULTS In the base case analysis, the addition of necitumumab to the treatment regimen produced an incremental survival benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs). The probabilistic sensitivity analyses established that when necitumumab cost less than $563 and less than $1309 per cycle, there was 90% confidence that the ICER for adding necitumumab would be less than $100 000 per QALY and less than $200 000 per QALY, respectively. CONCLUSIONS AND RELEVANCE These findings provide a value-based range for the cost of necitumumab from $563 to $1309 per cycle. This study provides a framework for establishing value-based pricing for new oncology drugs entering the US marketplace.

UR - http://www.scopus.com/inward/record.url?scp=84983516579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983516579&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2015.3316

DO - 10.1001/jamaoncol.2015.3316

M3 - Article

VL - 1

SP - 1293

EP - 1300

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 9

ER -

Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Ramalingam SS et al. Necitumumab in metastatic squamous cell lung cancer. JAMA Oncology. 2015 Dec 1;1(9):1293-1300. https://doi.org/10.1001/jamaoncol.2015.3316